Improving Outcomes in Non-Small Cell Lung Cancer
FDA Clears IND Application for LB2102 in Extensive-Stage SCLC
January 18, 2023The FDA has cleared Legend Biotech’s Investigational New Drug application for LB2102, an autologous chimeric antigen receptor T-cell therapy for the treatment of adult patients with extensive stage small-cell lung cancer...
FDA Approves Mirati's Lung Cancer Drug
December 15, 2022The U.S. Food and Drug Administration approved Mirati Therapeutics Inc's lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading...
U.S. FDA Declines To Approve Spectrum's Lung Cancer Drug
December 6, 2022Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration (FDA) declined to approve its experimental lung cancer drug due to...
Amgen Says Lumakras Cuts Risk of Lung Cancer Progression by 34%
October 4, 2022Amgen Inc's Lumakras [sotorasib] pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial...
US FDA Panel Votes Against Spectrum's Lung Cancer Drug
September 26, 2022Advisers to the U.S Food and Drug Administration on Thursday voted against recommending Spectrum Pharmaceuticals' experimental drug for the treatment of patients with a form of non-small cell lung cancer...
Sotorasib Improves PFS, ORR in Patients with NSCLC, KRAS G12C Mutations
September 12, 2022Treatment with sotorasib, an oral KRAS G12C inhibitor, was associated with superior progression-free survival and overall response rate when compared with standard-of-care docetaxel for patients with previously treated non-small cell lung cancer...
